Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Praziquantel

FDA-approved product (tablet, oral), marketed as Biltricide, Praziquantel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Praziquantel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis
  • Infection
  • Opisthorchiasis
  • Schistosomiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Quinoline derivatives and related substances
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02BA01; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Praziquantel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Praziquantel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes

    NCT01541631 · start 2012-05

    Registered record
    Registry ID
    NCT01541631
    Conditions
    Anemia; Intestinal Helminthiasis; Intestinal Schistosomiasis; Human Immunodeficiency Virus I Infection; Hematologic Diseases; Opportunistic Infections
    Interventions
    Praziquantel and Albendazole; Praziquantel and Albendazole; Praziquantel and Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2012-05
    Completion
    2013-06
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnemia; Intestinal Helminthiasis; Intestinal Schistosomiasis; Human Immunodeficiency Virus I Infection +2 more
    InterventionPraziquantel and Albendazole; Praziquantel and Albendazole; Praziquantel and Albendazole
    PhaseNot applicable
    Registry statusUnknown

  • Praziquantel-Pharmacokinetic Study

    NCT01288872 · start 2012-01

    Registered record
    Registry ID
    NCT01288872
    Conditions
    Schistosomiasis
    Interventions
    Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-08
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    InterventionPraziquantel
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Mirazid for Schistosomiasis Treatment

    NCT01529710 · start 2011-12

    Registered record
    Registry ID
    NCT01529710
    Conditions
    Schistosoma Hematobium Infection; Schistosomiasis Mansoni
    Interventions
    Myrrh
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2012-09
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosoma Hematobium Infection; Schistosomiasis Mansoni
    InterventionMyrrh
    PhasePhase 3
    Registry statusCompleted

  • Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

    NCT02366884 · start 2011-07-26

    Registered record
    Registry ID
    NCT02366884
    Conditions
    Neoplasms
    Interventions
    Anti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-07-26
    Completion
    2023-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionAnti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    PhasePhase 2
    Registry statusUnknown

  • Schistosoma Mansoni in Mwanza Region, Tanzania

    NCT02162875 · start 2011-03

    Registered record
    Registry ID
    NCT02162875
    Conditions
    Schistosoma Mansoni
    Interventions
    Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-03
    Completion
    2017-01
    Enrolment
    37,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosoma Mansoni
    InterventionPraziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana

    NCT01459146 · start 2010-12

    Registered record
    Registry ID
    NCT01459146
    Conditions
    Malaria; Schistosomiasis; Helminthiasis; Anemia; Change in Sustained Attention
    Interventions
    Artemether-lumefantrine combination plus albendazole; Artemether-lumefantrine plus Praziquantel plus Albendazole; Albendazole plus Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-12
    Completion
    2012-11
    Enrolment
    345

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Schistosomiasis; Helminthiasis; Anemia +1 more
    InterventionArtemether-lumefantrine combination plus albendazole; Artemether-lumefantrine plus Praziquantel plus Albendazole; Albendazole plus Praziquantel
    PhasePhase 4
    Registry statusUnknown

  • Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa

    NCT01154907 · start 2010-04

    Registered record
    Registry ID
    NCT01154907
    Conditions
    Uro-genital Schistosomiasis
    Interventions
    Praziquantel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2021-12
    Enrolment
    6,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUro-genital Schistosomiasis
    InterventionPraziquantel
    PhaseNot recorded
    Registry statusUnknown

  • Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

    NCT00441285 · start 2010-01

    Registered record
    Registry ID
    NCT00441285
    Conditions
    Neurocysticercosis; Epilepsy
    Interventions
    Praziquantel; Albendazole; ABZ Placebo; PZQ Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2013-09
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis; Epilepsy
    InterventionPraziquantel; Albendazole; ABZ Placebo; PZQ Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis

    NCT01260012 · start 2010-01

    Registered record
    Registry ID
    NCT01260012
    Conditions
    Schistosomiasis; Liver Fibrosis; Periportal Fibrosis; Oxidative Stress
    Interventions
    Praziquantel+antioxidant suppl; Praziquantel + placebo 2mths then antioxidant for 10 mths; Praziquantel therapy and placebo as supplement; Praziquantel+antioxidant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-01
    Completion
    2015-12
    Enrolment
    414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis; Liver Fibrosis; Periportal Fibrosis; Oxidative Stress
    InterventionPraziquantel+antioxidant suppl; Praziquantel + placebo 2mths then antioxidant for 10 mths; Praziquantel therapy and placebo as supplement; Praziquantel+antioxidant
    PhaseNot applicable
    Registry statusUnknown

  • A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni

    NCT01054651 · start 2009-10

    Registered record
    Registry ID
    NCT01054651
    Conditions
    Schistosoma Mansoni
    Interventions
    Artesunate+Sulfamethoxypyrazine/pyrimethamine; Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2009-12
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosoma Mansoni
    InterventionArtesunate+Sulfamethoxypyrazine/pyrimethamine; Praziquantel
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium

    NCT00870649 · start 2009-02

    Registered record
    Registry ID
    NCT00870649
    Conditions
    Urinary Schistosomiasis; Schistosoma Haematobium
    Interventions
    Bilhvax vaccine (Sh28GST); placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-02
    Completion
    2012-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Schistosomiasis; Schistosoma Haematobium
    InterventionBilhvax vaccine (Sh28GST); placebo
    PhasePhase 3
    Registry statusCompleted

  • Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

    NCT00507221 · start 2008-02

    Registered record
    Registry ID
    NCT00507221
    Conditions
    HIV Infections; Helminthiasis
    Interventions
    Albendazole; Praziquantel; Current standard of care in Kenya
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-02
    Completion
    2011-10
    Enrolment
    948

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Helminthiasis
    InterventionAlbendazole; Praziquantel; Current standard of care in Kenya
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Drug Combinations Against Schistosomiasis

    NCT01050374 · start 2007-10

    Registered record
    Registry ID
    NCT01050374
    Conditions
    Parasitic Diseases
    Interventions
    albendazole + praziquantel; mebendazole + praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-10
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParasitic Diseases
    Interventionalbendazole + praziquantel; mebendazole + praziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Drug Combinations Against Triple Infections

    NCT01050517 · start 2007-10

    Registered record
    Registry ID
    NCT01050517
    Conditions
    Parasitic Diseases
    Interventions
    albendazole + ivermectin + praziquantel; albendazole + ivermectin + (1 week later) praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-10
    Completion
    2007-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParasitic Diseases
    Interventionalbendazole + ivermectin + praziquantel; albendazole + ivermectin + (1 week later) praziquantel
    PhaseNot applicable
    Registry statusCompleted

  • S. Japonicum and Pregnancy Outcomes

    NCT00486863 · start 2007-08

    Registered record
    Registry ID
    NCT00486863
    Conditions
    Schistosomiasis
    Interventions
    Praziquantel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2012-11
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    InterventionPraziquantel; Placebo
    PhasePhase 2
    Registry statusCompleted